Last reviewed · How we verify

IPTc+CCM

Cheikh Anta Diop University, Senegal · Phase 3 active Small molecule

IPTc+CCM combines intermittent preventive treatment with community case management to reduce malaria transmission and clinical disease in endemic populations.

IPTc+CCM combines intermittent preventive treatment with community case management to reduce malaria transmission and clinical disease in endemic populations. Used for Malaria prevention and case management in children in endemic regions.

At a glance

Generic nameIPTc+CCM
SponsorCheikh Anta Diop University, Senegal
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

IPTc (Intermittent Preventive Treatment in children) involves periodic antimalarial drug administration to prevent malaria infection, while CCM (Community Case Management) enables rapid diagnosis and treatment of malaria cases at the community level. Together, this integrated approach targets both prevention through chemoprophylaxis and prompt case management to reduce overall malaria burden.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: